Abstract
OBJECTIVE: This study investigates the predictive value of CK-MB in treating acute myocardial infarction (AMI) with urokinase combined with low molecular weight heparin (LMWH) calcium. METHODS: AMI patients treated at our hospital from April 2020 to August 2022 were included in this prospective, multi-center cohort study. Patients were randomly assigned to a urokinase group or a combined treatment group (urokinase plus LMWH). CK-MB levels were measured using ELISA, and adverse reactions were recorded. The accuracy of CK-MB as a predictor was evaluated via ROC curve analysis and AUC. RESULTS: Before treatment, CK-MB levels were similar in both groups (p > 0.05). Post-treatment, levels were significantly lower in the combined group (p < 0.05). The combined group had a higher proportion of mild CK-MB elevation and lower moderate/severe elevations (p < 0.05). Adverse reaction rates were similar (p > 0.05). The combined treatment group showed higher effectiveness (p < 0.05), with better sensitivity (94%) and specificity (82%) than the urokinase group (sensitivity 89%, specificity 78%). CONCLUSION: CK-MB is a valuable predictor for evaluating the efficacy of urokinase plus LMWH in AMI treatment, offering advantages in reducing CK-MB levels and improving outcomes.